Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mauna Kea TechnologiesLTS:0P5I 46 EPS without NRI is €0.10 as of Dec. 2025. GuruFocus rates LTS:0P5I with a GF Score™ of 46/100 and a GF Value™ of €0.13 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 660 Medical Devices & Instruments companies, Mauna Kea Technologies ranks worse than 151515% on this metric.
Mauna Kea Technologies's earnings per share without non-recurring items for the
six
months ended in Dec. 2025 was €0.19.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was €0.10.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Mauna Kea Technologies's EPS without NRI or its related term are showing as below:
During the past 13 years, Mauna Kea Technologies's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 42.50% per year. The lowest was -11.80% per year. And the median was 13.40% per year.
LTS:0P5I's 3-Year EPS without NRI Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 8.15 * Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
Mauna Kea Technologies (LTS:0P5I) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Mauna Kea Technologies EPS without NRI Related Terms
Mauna Kea Technologies EPS without NRI Historical Data
* Premium members only.
The historical data trend for Mauna Kea Technologies's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0P5I vs ABT, SYK, MDT: EPS without NRI Comparison
For the Medical Devices subindustry, Mauna Kea Technologies's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mauna Kea Technologies PE Ratio without NRI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Mauna Kea Technologies's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Mauna Kea Technologies's PE Ratio without NRI falls into.
Mauna Kea Technologies EPS without NRI Calculation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.10
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mauna Kea Technologies (LTS:0P5I) has a EPS without NRI of €0.10 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Mauna Kea Technologies and its competitors. According to the industry distribution chart, Mauna Kea Technologies ranks #999999 out of 660 companies in the Medical Devices & Instruments industry.
Is Mauna Kea Technologies' EPS without NRI too high?
Mauna Kea Technologies' current EPS without NRI is €0.10. Based on the distribution chart, Mauna Kea Technologies ranks #999999 out of 660 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Mauna Kea Technologies has a GF Score™ of 46/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mauna Kea Technologies' EPS without NRI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Mauna Kea Technologies ranks #999999 out of 660 companies for EPS without NRI. This places Mauna Kea Technologies in the lower half of its industry. The industry median EPS without NRI is 8.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Devices & Instruments company?
The median EPS without NRI among Medical Devices & Instruments companies is 8.15, based on 660 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Mauna Kea Technologies and its competitors. For the Medical Devices & Instruments industry, the median EPS without NRI is 8.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mauna Kea Technologies's current EPS without NRI is €0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mauna Kea Technologies stock overvalued right now?
Based on GuruFocus' analysis, Mauna Kea Technologies (LTS:0P5I) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.13, compared to a current price of €0.15 — trading 19.1% above its estimated fair value. The current EPS without NRI is €0.10. Mauna Kea Technologies' overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Mauna Kea Technologies (LTS:0P5I), the current EPS without NRI is €0.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mauna Kea Technologies (LTS:0P5I) Overvalued in 2026?
Based on GuruFocus' analysis, Mauna Kea Technologies stock appears to be overvalued.
The current stock price of €0.15 is trading 19.1% above its estimated GF Value™ of €0.13.
GuruFocus considers Mauna Kea Technologies to be Modestly Overvalued.
Key valuation signals for LTS:0P5I:
EPS without NRI: €0.10
GF Value™: €0.13 vs. price of €0.15 (19.1% above fair value)
No single metric tells the full story. See the LTS:0P5I stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mauna Kea Technologies SA is a medical device company that develops, manufactures and markets an imaging platform for visualizing tissue at the cellular level, in real time, during standard procedures, with the mission of eliminating uncertainties in diagnosis and treatment through direct visualization of tissue in vivo at the microscopic level. The company's flagship product, Cellvizio, is the smallest microscope, designed for direct use during minimally invasive procedures. It operates in a single business segment: endomicroscopy. Its geographical presence includes EMEA (Europe, Middle East, Africa), USA and Canada, and Asia, of which the majority of the revenue is generated from USA and Canada.
46GF Score
Get the complete analysis for LTS:0P5I
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0P5I has been successfully added to your 
